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Background: Recent data suggests that high-flow oxygen started promptly after stroke symptom onset salvages
ischemic brain tissue. We investigated the consistency of oxygen delivery to suspected stroke patients in the
pre-hospital (PH) and Emergency Department (ED) settings, and associated adverse events (AEs).
Methods: We retrospectively reviewed pre-hospital call reports of suspected stroke patients transported by our
institution’s paramedics. We extracted data on oxygen delivery in the PH and ED settings, demographics, Glasgow
Coma Scale score (GCS), final diagnosis, and selected AEs (mortality, seizures, worsening neurological status, new
infarction, and post-ischemic hemorrhage). Patients were grouped according to ED oxygen delivery: none, low-flow
(2-4 L/min), and high-flow (10-15 L/min).
Results: Oxygen delivery was documented in 84% of 366 stroke transports, with 98% receiving 10-15 L/min. Our
hospital received 164 patients. Oxygen delivery in the ED was documented in 150 patients, with 38% receiving
none, 47% low-flow, and 15% high-flow oxygen. There were no instances of oxygen refusal, premature termination,
or technical difficulties. Advanced age and low GCS predicted the use of higher flow rates. High-flow oxygen was
more frequently administered to patients with symptom onset < 3 hours, and those with intracerebral hemorrhage
(ICH), hypoxic-ischemic encephalopathy (HIE) or seizures (p < 0.001). More patients receiving high-flow oxygen were
documented to have an AE (p = 0.02), however the low- and no-oxygen groups more frequently had multiple AEs
(p = 0.01). The occurrence of AEs was predicted by the diagnosis of ICH/HIE/seizures (p = 0.013) and acute ischemic
stroke (AIS)/transient ischemic attack (TIA) (p = 0.009), but not by the amount of oxygen.
Conclusions: Suspected stroke patients routinely receive 10–15 L/min oxygen in the ambulance however in the ED
there is wide variability due to factors such as clinical severity. Oxygen delivery appears safe in the PH and ED
settings.Introduction
Patients with suspected stroke usually receive supple-
mental oxygen in the pre-hospital (PH) and emergency
department (ED) settings, and oxygen is often continued
after hospital admission. The dose and duration of oxy-
gen delivery can vary in each of these clinical settings.* Correspondence: Yu-fengyvonne.chan@mountsinai.org
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unless otherwise stated.The reasons for this variability are not clear, but in part
may be explained by differences in pre-hospital and in-
hospital guidelines for oxygen delivery. Paramedics favor
oxygen delivery and most EMS Guidelines recommend
administering high flow rates (10-15 L/min) regardless
of physiologic need. Conversely, the latest AHA Stroke
Treatment Guidelines [1] recommend supplemental oxy-
gen in acute stroke only if required to maintain peripheral
oxygen saturation (SaO2) levels above 92%. The evidence
basis for these guidelines is relatively lacking; indeed, the
threshold SaO2 level below which supplemental oxygen is
recommended by the AHA has varied from 92% to 95%
over the last decade.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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have been the subject of discussion for several decades
[2-5]. Interest in a therapeutic role of oxygen in acute is-
chemic stroke (AIS) has recently been kindled by the re-
sults of over 120 animal studies [2-8] and pilot human
studies [9-11] suggesting that the delivery of high-flow
oxygen promptly after symptom onset (normobaric oxy-
gen therapy, or NBO) affords neuroprotection and may
have therapeutic potential by increasing the 3-hour time
window for thrombolysis with intravenous tissue plas-
minogen activator (IV tPA). Our group and others have
previously published and demonstrated that NBO can
“freeze” the ischemic penumbra and extend the time win-
dow for thrombolysis in rodent stroke models through
hemodynamic effects, improved tissue oxygenation, and
biochemical mechanisms [2,6,12-14]. These recent NBO
studies suggest that a paradigm of 10-15 L/min oxygen
delivery – if initiated within an appropriate time window
and delivered consistently for several hours in both the
PH and ED settings – may provide hypoxic brain tissue
oxygen, delay ischemic cell death, afford more time for ar-
terial recanalization to occur, and ultimately improve out-
comes after stoke [3,15]. Furthermore, literature supports
that treating AIS patients with short durations of NBO or
low hyperbaric oxygen is very unlikely to cause oxidative
stress [16,17].
In this study we investigated the consistency of oxygen
delivery in the PH and ED settings and relevant adverse
events in the PH, ED, and inpatient settings among pa-
tients with suspected stroke.
Methods
Subjects
This retrospective study was conducted at our institution
(Mount Sinai Medical Center, a designated stroke center)
after approval by our Human Research Committee. Our
institution’s EMS service transports patients to several
New York City hospitals, including ours. We searched the
pre-hospital call reports for consecutive patients with a
presumptive diagnosis of ‘cerebral vascular accident’
encountered by our institution's EMS service from
November 2003 to October 2008. We had no additional
exclusion criteria for patient selection in our study. We
extracted data on patient demographics, PH oxygen de-
livery, and PH adverse events for all patients. For the
subgroup of patients brought to our institution's ED,
we collected additional data on ED oxygen delivery, the
inpatient medical course (for admitted patients), and
relevant AEs occurring during the ED stay or inpatient
admission.
Oxygen delivery
Pre-hospital call reports and ED documentation were
reviewed for completeness regarding oxygen administration.The feasibility of supplemental oxygen delivery in the
PH and ED settings was evaluated by reviewing relevant
documentation of any interruptions to oxygen adminis-
tration and recording the reason for interruption.
Nearly all patients (98%) received high flow (10-15 L/min)
oxygen in the PH setting. Hence, patients were grouped
according to oxygen delivery in the ED: (1) no supplemen-
tal oxygen, (2) low-oxygen (2-4 L/min), and (3) high-
oxygen (10-15 L/min). For patients with changing rates of
oxygen delivery, group assignment was based on the flow
rate used for the longest duration. The rate of oxygen de-
livery (L/min) was coded as missing if not clearly docu-
mented, even if the medical records suggested that oxygen
was administered. Patients undergoing endotracheal in-
tubation were assigned to the high-oxygen group because
such patients usually receive 100% oxygen around the
time of intubation and thereafter during mechanical
ventilation.
Adverse events
The following adverse events (AEs) were deemed relevant
based on the known clinical adverse effects of oxygen de-
livery and preclinical data raising potential concern for
oxygen free radical injury: in-hospital mortality, seizures,
and neurological decline (new altered mental status or
new or worsening focal neurological deficits). For patients
with the final diagnosis of ischemic stroke or transient is-
chemic attack (TIA), we also collected data on post-
ischemic hemorrhage (any hemorrhage on a follow-up
head CT or brain MRI), and recurrent ischemic stroke
(new infarct in a different arterial territory on follow-up
head CT or brain MRI). We assessed the relationship be-
tween the AEs and the amount of oxygen exposure, in
subgroups based upon final diagnosis and the Glascow
Coma Scale (GCS) score, which reflects clinical severity
and is routinely documented in the ED.
Statistical analysis
Data analysis was performed using SPSS (SPSS Inc. ver-
sion 17.0, Chicago, IL). Student t test, Chi-square test,
Fisher Exact test, or analysis of variance (ANOVA) was
used as appropriate. Logistic regression analysis was per-
formed to determine independent predictors of AEs, with
Odds Ratios (O.R.) and 95% confidence intervals (C.I.). A
value of P < 0.05 was considered statistically significant.
Results
Pre-hospital call records showed that 366 patients with
suspected stroke were transported to 15 hospitals during
the timeframe of this study, including 164 patients (45%)
transferred to Mount Sinai Hospital’s ED and 202 (55%)
to other EDs. Supplemental oxygen delivery was docu-
mented in 307 patients (84%) with 301 (98%) receiving
high-flow oxygen. Documentation of PH oxygen delivery
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other hospitals (90% versus 79%, p = 0.003), however in
both groups in whom PH oxygen delivery was docu-
mented, 98% of patients received high-flow oxygen. There
was no significant difference in the mean age (69 ± 15 vs.
71 ± 15 years, p = 0.22), female gender (61% vs. 63%, p =
0.86), mean on-scene time (24.5 vs. 25.2 minutes, p = 0.28),
mean transport time (4.4 vs 5.0 minutes, p = 0.19), or mean
PH GCS score (13 ± 3 vs. 13 ± 3, p = 0.86) between the
group of patients transported to Mount Sinai versus other
hospitals. Among the 164 Mount Sinai transports, the time
of symptom onset or last seen well was documented in 107
patients (65%), of whom 62 (58%) arrived within the 3-
hour time window for IV t-PA approved by the U.S. Food
and Drug Administration. The rest arrived between 3–24
hours (22 patients, 21%) or >24 hours after symptom onset
(23 patients, 21%).
Oxygen delivery status in the ED was documented in
150 patients (91%). These patients formed the denomin-
ator for subsequent analysis. PH oxygen delivery was
documented in 134 patients (89%; 133 received high-
flow oxygen and one received 2 L/min). In the ED, 57
(38%) received no supplemental oxygen, 70 (47%) re-
ceived low-flow oxygen, and 23 (15%) received high-flow
oxygen. We found no instances of patient or caregiver
refusal of oxygen, disruption, premature termination, or
logistical or technical difficulties related to oxygen deliv-
ery in the PH or ED settings.
Table 1 shows the characteristics of the 150 ED patients
according to the category of oxygen delivery. There were
significant differences in the mean age, onset to ED arrival
times, initial GCS score, hospital admission status and in-
tubation status between the 3 oxygen delivery groups.
High-flow oxygen delivery tended to be common in
women and those with worse GCS scores. Furthermore, of
the 107 patients with documented time of symptom onset,
the 62 that arrived to the ED within 3 hours of onset were
more likely to receive high-flow oxygen than those pre-
senting >3 hours or had unknown time of onset. Logistic
regression analysis showed that advanced age (O.R. 1.02,
95% C.I. 1.00-1.06, p = 0.045) and poor GCS (O.R. 0.09,
95% C.I. 0.01-0.7, p = 0.02) but not sex (O.R. 1.3, 95% C.I.
0.6-2.8, p = 0.46) predicted the amount of oxygen delivery.
Most patients receiving low or high dose oxygen were
eventually admitted to the hospital. The final diagnosis
was acute ischemic stroke in 56 patients (37%, 4 received
IV tPA), TIA in 4 (3%), intracerebral hemorrhage in 16
(ICH, 11%), hypoxic-ischemic encephalopathy in 5 (HIE,
3%), toxic-metabolic encephalopathy in 38 (25%), seizure
in 11 (7%), and miscellaneous conditions such as Bells’
palsy, brain tumor, and multiple sclerosis in 20 patients
(13%). The amount of oxygen delivered varied signifi-
cantly according to the underlying diagnosis (p < 0.001)
with high-flow oxygen delivery more frequent inpatients with ICH and HIE or seizures (p < 0.001) and
low-flow oxygen more frequent in patients with AIS or
TIA (p = 0.007). Of the 4 patients who received IV tPA,
one received PH oxygen only and the remaining three
continued to receive low-flow oxygen in the ED. Of the
AIS/TIA patients with known time of symptom onset,
21 (57%) arrived to the ED within 3 hours and 16 (43%)
arrived after 3 hours of symptom onset. Seventeen pa-
tients (11%) were discharged from the ED including
one with TIA. Among the 133 admitted patients, dis-
charge destination was known in 106 (80%); 36 went
home, 58 to rehab or nursing home, and 12 expired or
were discharged to a hospice facility.
Given the small sample size of AIS/TIA patients who
presented within the 3 hour time window, we were un-
able to determine the association between oxygen use
and clinical outcome (AEs) in this subset of patients.
Similarly, we could not determine if interaction exists
between tPA and oxygen use.
Pre-defined AEs were retrieved from medical records
for 126 of the 150 patients with oxygen delivery status
documented in the ED, including all 17 patients dis-
charged directly from the ED; the rest had incomplete or
missing records. The percentage of patients with any AE
documented tended to be higher in the high-flow oxygen
group (p = 0.07), however the percentage of specific AEs
such as mortality, seizures, neurological worsening, new
radiological infarcts, and post-ischemic hemorrhage,
were not significantly different between groups.
Table 2 shows subgroup comparisons among the 126
patients with complete AE data. Patients receiving high-
flow oxygen were more frequently documented to have
an AE (p = 0.02), however most patients in this group
had only one AE, while patients in the low-oxygen and
no supplemental oxygen groups more frequently had
multiple AEs (p = 0.01). We then examined the fre-
quency of AEs according to the final diagnosis. In the
AIS/TIA population, 15 of 53 patients (28%) were docu-
mented to have AEs and there was no significant differ-
ence in the percentage of patients with AEs, or specific
AEs such as mortality and neurological worsening,
across the 3 oxygen delivery groups. Among patients
with a final diagnosis of ICH, HIE or seizures, 10 of 28
patients (36%) were documented to have AEs with 8 pa-
tients in the high-flow oxygen group (p = 0.06). Lastly,
among patients with toxic/metabolic encephalopathy or
miscellaneous stroke mimics, only 2 of 45 patients (4%)
were documented to have AEs including one in the no
supplemental oxygen group and the other in the low-
flow oxygen group.
Logistic regression analysis showed that AE occurrence
was independently predicted by the final diagnosis of ICH/
HIE/seizures (O.R. 17.3, 95% C.I. 1.84-162.7, p = 0.013),
and AIS/TIA (O.R. 16.2, 95% C.I. 2.0-132.3, p = 0.009), but
Table 1 Patient characteristics
No suppl. oxygen (n=57) Low-flow oxygen (n=70) High flow oxygen (n=23) P value
Age 65.3±15.6 73.6±13.3 65.5±16.5 0.003
Males 26 (46%) 25 (36%) 4 (17%) 0.06
Symptom onset to ED time
Less than 3 hrs 17 (30%) 30 (43%) 11 (48%)
More than 3 hrs 25 (44%) 17 (24%) 2 (9%) 0.02
Unknown 15 (26%) 23 (33%) 10 (43%)
Initial GCS score
0-8 1 (2%) 6 (9%) 8 (35%)
9-15 53 (93%) 57 (81%) 12 (52%) <0.001
Missing 3 (5%) 7 (10%) 3 (13%)
Inpatient admission 44 (77%) 67 (96%) 22 (96%) 0.002
Intubation 0 (0%) 0 (0%) 17 (74%) <0.001
Discharge destination
Home 25 (44%) 24 (34%) 3 (13%)
Rehab/Dead 22 (39%) 33 (47%) 15 (65%) 0.13
Unknown 10 (18%) 13 (19%) 5 (22%)
Final Diagnosis
AIS or TIA 22 (39%) 35 (50%) 3 (13%)
Hemorrhagic stroke 2 (4%) 6 (9%) 8 (35%)
HIE or Seizures 4 (7%) 4 (6%) 8 (35%) <0.001
Toxic/metabolic 18 (32%) 17 (24%) 3 (13%)
Miscellaneous 11 (19%) 8 (11%) 1 (4%)
Adverse Events*
None 43 (75%) 46 (66%) 10 (44%)
Present 6 (11%) 13 (19%) 8 (35%) 0.07
Unknown 8 (14%) 11 (16%) 5 (22%)
Specific Adverse Events
Mortality 2 (4%) 5 (7%) 4 (17%) 0.2
Seizures 2 (4%) 4 (6%) 1 (4%) 0.9
New neurological deficit 4 (7%) 6 (9%) 2 (9%) 0.9
New infarction 1 (2%) 1 (1%) 1 (4%) 0.8
Post-ischemic hemorrhage 2 (4%) 6 (9%) 1 (4%) 0.7
*None of the adverse events occurred in patients discharged from the ED.
Abbreviations: ED emergency department, GCS Glasgow Coma Scale, AIS acute ischemic stroke, TIA transient ischemic attack, HIE hypoxic-ischemic encephalopathy.
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p = 0.23) or the GCS category (O.R. 0.8, 95% C.I. 0.7-1.05,
p = 0.12). Linear regression analysis showed that the num-
ber of AEs was significantly associated with the final diag-
nosis of AIS/TIA (p < 0.001) and tended to be associated
with the GCS category (p = 0.08) but not the final diagnosis
of ICH/HIE/seizures (p = 0.12) or the oxygen delivery cat-
egory (p = 0.66).
Discussion
In this study, we assessed the amount and consistency of
oxygen delivery in the initial hours after the onset ofstroke-like symptoms, and its effect on immediate and
delayed in-hospital adverse events. The motivation for
this study comes from the overwhelmingly positive re-
sults of several rodent and pilot human studies showing
that high concentrations of oxygen administered soon
after ischemic stroke onset has potential to slow down
the process of ischemic necrosis [2-11]. Hyperoxia’s
pluripotent effects on molecular and biochemical path-
ways of ischemic neuronal death have been associated
with reduced pathological infarct volumes, transient rever-
sal of diffusion-MRI abnormalities, improved lactate levels,
improved cerebral perfusion, and improved functional
Table 2 Adverse events by final diagnosis*
No suppl. oxygen (n=49) Low-flow oxygen (n=59) High flow oxygen (n=18) P value
Any AE Present 6 (12%) 13 (22%) 8 (44%) 0.02
1 AE 2 (4%) 7 (12%) 7 (39%)
2 AEs 3 (6%) 3 (5%) 1 (6%) 0.01
3 AEs 1 (2%) 3 (5%) 0 (0%)
Final Diagnosis
AIS/TIA (N=53) N=18 N=33 N=2
Any AE present 4 (22%) 11 (33%) 0 (0%) 0.47
Mortality 1 (6%) 4 (12%) 0 (0%) 0.67
Seizures 2 (11%) 3 (9%) 0 (0%) 0.87
New neurological deficit 3 (17%) 6 (18%) 0 (0%) 0.80
New ischemic lesion 1 (6%) 1 (3%) 0 (0%) 0.87
Post-ischemic hemorrhage 2 (11%) 6 (18%) 0 (0%) 0.66
ICH/HIE/Seizures (N=28) N=6 N=8 N=14
Any AE present 1 (17%) 1 (13%) 8 (57%) 0.06
Mortality 1 (17%) 0 (0%) 4 (29%) 0.24
Seizures 0 (0%) 1 (13%) 1 (7%) 0.67
New neurological deficit 0 (0%) 0 (0%) 2 (14%) 0.34
New ischemic lesion 0 (0%) 0 (0%) 1 (7%) 0.60
Other (N=45) N=25 N=18 N=2
Any AE present 1 (4%) 1 (6%) 0 (0%) 0.9
Mortality 0 (0%) 1 (6%) 0 (0%) 0.5
New neurological deficit 1 (4%) 0 (0%) 0 (0%) 0.7
*Patients with missing data were excluded. Abbreviations: AE adverse event, AIS acute ischemic stroke, TIA transient ischemic attack, ICH hemorrhagic stroke,
HIE hypoxic-ischemic encephalopathy, GCS Glasgow Coma Scale.
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safety concerns, there is a theoretical risk of worsening
stroke outcome by hyperoxia-induced oxygen free radical
injury in hyperbaric oxygen treatment, cerebral vasocon-
striction, and systemic adverse effects such as infection and
respiratory depression [18]. Clinical trials are therefore
warranted to determine whether early hyperoxia (continu-
ous PH and ED oxygen therapy for a few hours) can safely
extend the time window for thrombolysis, or improve the
safety and efficacy of neuroprotective drugs by preventing
early neuronal and endothelial cell death. The results of
our study provide important information towards the de-
sign of such trials, which can impact stroke care around
the world.
Given our institution’s location in the NYC regional
EMS area, with established PH and ED oxygen delivery
guidelines [19,20], we had a unique opportunity to ex-
plore the use of oxygen in the PH and ED settings in is-
chemic stroke as well as stroke mimics. The high
frequency of oxygen administration and documentation
of oxygen use in the PH setting demonstrates compli-
ance with our PH oxygen delivery guidelines. Patients
with symptom onset <3 hours or unknown time of onsetmore often received high-flow oxygen. While oxygen de-
livery status was documented in 91% of patients in our
ED, there was variability in the amount delivered, reflect-
ing biases and uncertainties in continuing oxygen after
hospital arrival. Our data shows that patients who ap-
pear more ill, i.e. advanced age, low GCS, are more likely
to receive higher flow rates of oxygen after ED arrival,
but the flow rates selected were still variable. Nearly all
patients who continued to receive oxygen in the ED
were admitted, again suggesting that oxygen delivery is a
marker for disease severity. Unfortunately we did not in-
vestigate the duration and amount of oxygen delivery after
hospitalization. In a previous stroke study [21], approxi-
mately two-thirds received oxygen during hospitalization
however there was limited justification for either giving or
withholding oxygen. These data suggest opportunities to
refine and improve compliance with ED and in-hospital
oxygen delivery guidelines in acute stroke and other con-
ditions [22].
In the acute setting, it can be challenging to obtain ac-
curate information concerning chronic obstructive pul-
monary disease, a relative contraindication for oxygen
delivery. In our study no patient developed respiratory
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stances of refusal or technical difficulties with oxygen
delivery. No adverse event was recorded among the pa-
tients discharged from the ED. While these data suggest
safety and feasibility of the initial few minutes of oxygen
delivery in the PH setting, it is conceivable that our
paramedics withheld oxygen in patients with known
COPD. Caution is still required when administering oxy-
gen in the PH setting.
Next, we investigated the associated between oxygen
delivery and subsequent adverse events. As noted, AEs
were recorded solely among inpatients and not among
ED discharges. Among patients with known AE status,
the high-flow oxygen group had a significantly higher
frequency of developing one or more AEs however pa-
tients receiving low-flow or no supplemental oxygen
more often had multiple AEs. The group of patients with
a final diagnosis of ICH, HIE, or seizures, had the highest
frequency of AEs (36%), and patients with these diagnosis
typically have more dramatic presentations, consistent
with the above results showing a correlation between ad-
vanced age and lower GCS with oxygen delivery. Import-
antly, there was no significant difference in the occurrence
of individual AEs within the final diagnosis categories
(Table 2). There was no ‘pattern’ of AEs, for example
higher mortality of seizures, across diagnostic groups.
Only 4 of 45 patients in the stroke mimic group were re-
corded to have AEs, and none received high-flow oxygen.
Finally, the oxygen delivery category did not prove to be a
predictor of AEs in logistic and linear regression analyses.
These data support the hypothesis that AEs correlate to
the underlying disease process rather than the quantity of
oxygen delivery. Since oxygen therapy may not be related
to outcome, then our data also supports the safety of oxy-
gen delivery in suspected acute stroke and ischemic stroke
mimics. Furthermore, if the initial GCS score was a reli-
able indicator of disease severity, our data suggest that
high-flow oxygen may potentially have a therapeutic ef-
fect. Specifically, although the percentage of HF patients
(35%) with initial GCS ≤ 8 was seventeen times greater
than that of LF (2%), the percentage of HF patients (65%)
that had a discharge destination of rehab or dead was less
than twice of that of LF (39%).
Although ours is the first study investigating compli-
ance, feasibility and safety of PH and ED oxygen delivery
in acute stroke, we acknowledge several shortcomings.
The study was small, retrospective, single center, and
limited in data collection. We did not collect information
on the duration of oxygen, and hence could not adjust for
the total ‘dose’ of oxygen administered. Documentation of
oxygen delivery may not have been accurate in all cases.
We restricted our analysis to AEs considered relevant and
likely to be documented in clinical notes. Although hyper-
oxia can cause respiratory depression, we excludedrespiratory AEs since it was difficult to determine whether
oxygen caused such AEs or was administered to treat re-
spiratory AEs (significant confounding by indication). Fac-
tors such as stroke etiology, infarct or hemorrhage
volume, and co-morbidities, which contribute to in-
hospital AEs, were not examined. Nevertheless, our results
provide some insights and preliminary data concerning
the safety and use of oxygen in PH and ED settings.
Additional limitations to our study include the lack of
randomization and appropriately matched controls.
Biases may be introduced in the comparison of the
groups and the interpretation of the results. Given the
various constraints, including the feasibility and ethical
issues associated with a randomized control trial, we
chose the retrospective cohort design for our study. In
theory, it should offer a higher level of evidence/internal
validity than case–control design because we can dir-
ectly measure the absolute risk of and monitor the oc-
currence of multiple outcomes. Unfortunately, due to
the small sample size, we were unable use to statistical
techniques such as propensity score matching to help re-
duce potential bias. Also, we did not perform a power
analysis. However, given the aforementioned study con-
straints, we were only able to conduct a retrospective re-
view of the few years’ worth of medical records available
to us. Therefore, the primary objective of our study was
to establish feasibility and to describe the existing prac-
tice patterns of pre-hospital and Emergency Department
supplemental oxygen delivery. Our secondary aim was
to assess safety and report the adverse events observed
in our cohort.
Previous human studies of hyperbaric oxygen therapy
[23] and in-hospital supplemental oxygen [24] have not
shown benefit, perhaps due to their small size, delayed
treatment, and other trial design issues [25]. Most ex-
perts agree that a properly designed trial with oxygen
initiated within a very narrow time window, in the PH
and ED settings, is required to adequately test the thera-
peutic potential of oxygen in acute stroke. We envision
our data to be useful in designing such trials, preferably
multi-center, and hope that these trials commence in the
near future.
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